Investing.com -- Shares of Tevogen Bio experienced a significant surge following the announcement of an expanded collaboration with Microsoft (NASDAQ: MSFT ).

The biotech company is leveraging Microsoft's AI and cloud capabilities to develop its proprietary technology, PredicTcell.

The PredicTcell technology is being designed for predictive precision T-cell targeting. The collaboration with Microsoft is expected to aid in the development of this technology.

The stock was up 52% at $2.06 in premarket trading on Monday. This surge comes in contrast to the company's share price a year ago, which was recorded at $7.58.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.